Dynavax Technologies Q2 2024 Earnings Report $13.05 +0.04 (+0.31%) As of 01/31/2025 04:00 PM Eastern Earnings HistoryForecast Dynavax Technologies EPS ResultsActual EPS$0.08Consensus EPS $0.06Beat/MissBeat by +$0.02One Year Ago EPS$0.03Dynavax Technologies Revenue ResultsActual Revenue$73.80 millionExpected Revenue$76.92 millionBeat/MissMissed by -$3.12 millionYoY Revenue GrowthN/ADynavax Technologies Announcement DetailsQuarterQ2 2024Date8/6/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseDVAX Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Dynavax Technologies Earnings HeadlinesDynavax adds two new directors, announces board retirementsJanuary 30 at 1:59 AM | msn.comDynavax adds new directors, plans board declassificationJanuary 27, 2025 | msn.comBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin Skimming allows you to “skim” cash into your account thanks to 2025’s surging Bitcoin market.February 1, 2025 | Brownstone Research (Ad)Dynavax Technologies Corp (DVAX) Announces Strategic Board ChangesJanuary 27, 2025 | gurufocus.comDynavax Advances Board Refreshment ProgramJanuary 27, 2025 | prnewswire.comDynavax’s Strong Growth Potential Driven by Heplisav-B Sales and Strategic Market PositioningJanuary 14, 2025 | markets.businessinsider.comSee More Dynavax Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dynavax Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dynavax Technologies and other key companies, straight to your email. Email Address About Dynavax TechnologiesDynavax Technologies (NASDAQ:DVAX), a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.View Dynavax Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings PayPal (2/3/2025)Palantir Technologies (2/3/2025)NXP Semiconductors (2/3/2025)Mitsubishi UFJ Financial Group (2/3/2025)Mondelez International (2/4/2025)Advanced Micro Devices (2/4/2025)Alphabet (2/4/2025)Alphabet (2/4/2025)Amgen (2/4/2025)Banco Bilbao Vizcaya Argentaria (2/4/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
